Metraipolis › archive › dc_8cbbf027ab48
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk… — Europe PMC PMID:38451304
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/38451304
- DOI
- 10.1093/schbul/sbae011
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T00:35:13.305Z
- SHA-256 of the archived text
6918667c02cce49ae65ada73de34bf41c43be460eeb83d5c181d77aff8803d14- Stable URL of this page
https://metraipolis.com/documento/dc_8cbbf027ab48
How to cite
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk… — Europe PMC PMID:38451304 — Europe PMC (en), https://europepmc.org/article/MED/38451304 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8cbbf027ab48 (Metraipolis archive dc_8cbbf027ab48, sha256 6918667c02cce49ae65ada73de34bf41c43be460eeb83d5c181d77aff8803d14)
BibTeX
@misc{dc8cbbf027ab48,
title = {Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk… — Europe PMC PMID:38451304},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/38451304},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8cbbf027ab48; sha256 6918667c02cce49ae65ada73de34bf41c43be460eeb83d5c181d77aff8803d14},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/38451304. Agents can read the archived copy with the MCP tool read_document.